Drug Profile
Doxorubicin/encequidar - Athenex
Alternative Names: Doxorubicin + HM-30181A; Doxorubicin oral/encequidar oral- Athenex; Encequidar/doxorubicin - AthenexLatest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Developer Athenex
- Class Amides; Anthracyclines; Antineoplastics; Benzopyrans; Cytostatic antibiotics; Doxorubicins; Isoquinolines; Small molecules; Taxanes; Tetrazoles
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer